Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia

Journal of Clinical Oncology

Volumn 28, Issue 3, 2010, Pages 437-444

  Kantarjian, Hagop ^a   Fenaux, Pierre ^a   Sekeres, Mikkael A ^a   Becker, Pamela S ^a   Boruchov, Adam ^a   Bowen, David ^a   Hellstrom Lindberg, Eva ^a   Larson, Richard A ^a   Lyons, Roger M ^a   Muus, Petra ^a   Shammo, Jamile ^a   Siegel, Robert ^a   Hu, Kuolung ^a   Franklin, Janet ^a   Berger, Dietmar P ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ROMIPLOSTIM; FC RECEPTOR; HEMATOLOGIC AGENT; HYBRID PROTEIN; THROMBOPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; BLAST CELL; BLEEDING; BONE NECROSIS; BRAIN HEMORRHAGE; CANCER RISK; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GRANULOCYTIC SARCOMA; HEADACHE; HUMAN; MALE; MYELODYSPLASTIC SYNDROME; PRESYNCOPE; PRIORITY JOURNAL; SCORING SYSTEM; SIDE EFFECT; THROMBOCYTE; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS; TREATMENT DURATION; VERTIGO; MIDDLE AGED; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HEMATOLOGIC AGENTS; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RECEPTORS, FC; RECOMBINANT FUSION PROTEINS; THROMBOCYTOPENIA; THROMBOPOIETIN; TREATMENT OUTCOME;

EID: 75749124291     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.24.7999     Document Type: Article

References (21)

1. Greenberg PL, Young NS, Gattermann N: Myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program 136-161, 2002
2. Hofmann WK, Koeffler HP: Myelodysplastic syndrome. Annu Rev Med 56:1-16, 2005
3. Dansey R: Myelodysplasia. Curr Opin Oncol 12:13-21, 2000
4. Greenberg P, Cox C, LeBeau MM, et al: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079-2088, 1997
5. Kantarjian H, Giles F, List A, et al: The incidence and impact of thrombocytopenia in myelodysplastic syndromes. Cancer 109:1705-1714, 2007
6. Maldonado JE, Pierre RV: The platelets in preleukemia and myelomonocytic leukemia: Ultrastructural cytochemistry and cytogenetics. Mayo Clin Proc 50:573-587, 1975
7. Lintula R, Rasi V, Ikkala E, et al: Platelet function in preleukaemia. Scand J Haematol 26:65-71, 1981
8. Kantarjian H, O'Brien S, Ravandi F, et al: Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer 113:1351-1361, 2008
9. Kao JM, McMillan A, Greenberg PL: International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: Impact of cytopenias on clinical outcomes in myelodysplastic syndromes. Am J Hematol 83:765-770, 2008
10. Sekeres MA, Schoonen WM, Kantarjian H, et al: Characteristics of US patients with myelodysplastic syndromes: Results of six cross-sectional physician surveys. J Natl Cancer Inst 100:1542-1551, 2008
11. Goodnough LT, DiPersio JF: Issues in the management of cancer-related thrombocytopenia. Oncology (Williston Park) 16:1558-1567, 2002; discussion 1570:1572-1574, 2002
12. Schiffer CA, Anderson KC, Bennett CL, et al: Platelet transfusion for patients with cancer: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19:1519-1538, 2001
13. Kuter DJ, Bussel JB, Lyons RM, et al: Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: A double-blind randomised controlled trial. Lancet 371:395-403, 2008
14. Wang B, Nichol JL, Sullivan JT: Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther 76:628-638, 2004
15. Harris NL, Jaffe ES, Diebold J, et al: The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Ann Oncol 10:1419-1432, 1999
16. Cheson BD, Bennett JM, Kantarjian H, et al: Report of an International Working Group to standardize response criteria for myelodysplastic syndromes. Blood 96:3671-3674, 2000
17. Cheson BD, Greenberg PL, Bennett JM, et al: Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 108: 419-425, 2006
18. Choi ES, Hokom MM, Chen JL, et al: The role of megakaryocyte growth and development factor in terminal stages of thrombopoiesis. Br J Haematol 95:227-233, 1996
19. Corazza F, Hermans C, D'Hondt S, et al: Circulating thrombopoietin as an in vivo growth factor for blast cells in acute myeloid leukemia. Blood 107:2525-2530, 2006
20. Fontenay-Roupie M, Dupont JM, Picard F, et al: Analysis of megakaryocyte growth and development factor (thrombopoietin) effects on blast cell and megakaryocyte growth in myelodysplasia. Leuk Res 22:527-535, 1998
21. Meyerson HJ, Farhi DC, Rosenthal NS: Transient increase in blasts mimicking acute leukemia and progressing myelodysplasia in patients receiving growth factor. Am J Clin Pathol 109:675-681, 1998